Next Article in Journal
Chitosan Improves Anti-Biofilm Efficacy of Gentamicin through Facilitating Antibiotic Penetration
Previous Article in Journal
Lung Injury Induced by TiO2 Nanoparticles Depends on Their Structural Features: Size, Shape, Crystal Phases, and Surface Coating
Previous Article in Special Issue
Targeting Dendritic Cell Function during Systemic Autoimmunity to Restore Tolerance

Smoking and Rheumatoid Arthritis

Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne 3800, Australia
Department of Pediatrics, Severance Children's Hospital, Yonsei University College of Medicine, Seoul 120-752, Korea
Department of Pediatrics, Pusan National University Children's Hospital, Yangsan 626-770, Korea
Department of Pediatrics, Jeju National University School of Medicine, Jeju 690-767, Korea
Department of Pediatrics, Ajou University School of Medicine, Daewoo General Hospital, Geoje 656-711, Korea
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2014, 15(12), 22279-22295;
Received: 27 August 2014 / Revised: 11 October 2014 / Accepted: 17 October 2014 / Published: 3 December 2014
(This article belongs to the Special Issue Environmental Toxicants and Autoimmune Disease)
Rheumatoid arthritis (RA) is a chronic inflammatory disease caused by both genetic and environmental factors. Smoking has been implicated as one of the most important extrinsic risk factors for its development and severity. Recent developments have shed light on the pathophysiology of RA in smokers, including oxidative stress, inflammation, autoantibody formation and epigenetic changes. The association of smoking and the development of RA have been demonstrated through epidemiologic studies, as well as through in vivo and animal models of RA. With increased use of biological agents in addition to standard disease-modifying antirheumatic drugs (DMARDs), there has been interest in how smoking affects drug response in RA treatment. Recent evidence suggests the response and drug survival in people treated with anti-tumour necrosis factor (anti-TNF) therapy is poorer in heavy smokers, and possible immunological mechanisms for this effect are presented in the current paper. View Full-Text
Keywords: rheumatoid arthritis; smoking; cyclic citrullinated peptide; synovial fibroblasts; drug response rheumatoid arthritis; smoking; cyclic citrullinated peptide; synovial fibroblasts; drug response
MDPI and ACS Style

Chang, K.; Yang, S.M.; Kim, S.H.; Han, K.H.; Park, S.J.; Shin, J.I. Smoking and Rheumatoid Arthritis. Int. J. Mol. Sci. 2014, 15, 22279-22295.

AMA Style

Chang K, Yang SM, Kim SH, Han KH, Park SJ, Shin JI. Smoking and Rheumatoid Arthritis. International Journal of Molecular Sciences. 2014; 15(12):22279-22295.

Chicago/Turabian Style

Chang, Kathleen, So Min Yang, Seong Heon Kim, Kyoung Hee Han, Se Jin Park, and Jae Il Shin. 2014. "Smoking and Rheumatoid Arthritis" International Journal of Molecular Sciences 15, no. 12: 22279-22295.

Find Other Styles

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop